AC Immune SA, a clinical-stage biopharma company developing therapeutics for neurodegenerative diseases, and Eli Lilly and Co. have amended their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer candidates and potential back-up compounds. Unde...